Quick Answer
FibroBiologics, Inc. reported Diluted EPS of $0.42 per share (loss) for fiscal year 2025.
FibroBiologics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.42 | -23.5% |
| 2024 | -$0.34 | +50.0% |
| 2023 | -$0.68 | -277.8% |
| 2022 | -$0.18 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | -1200.0% | -8.3% |
| June 30, 2025 | -$0.12 | -500.0% | +14.3% |
| March 31, 2025 | -$0.14 | +48.1% | -1300.0% |
| September 30, 2024 | -$0.01 | +87.5% | -133.3% |
| June 30, 2024 | $0.03 | +137.5% | +111.1% |
| March 31, 2024 | -$0.27 | -50.0% | -237.5% |
| September 30, 2023 | -$0.08 | — | +0.0% |
| June 30, 2023 | -$0.08 | — | +55.6% |
- FibroBiologics, Inc. showed a decrease of -23.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, FibroBiologics, Inc.’s diluted eps has declined by 133.3% (from $0.18 per share (loss) to $0.42 per share (loss)).
- The most recent figure is from FibroBiologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: